Study On Alteration Of P16 Gene And Its Coexpression With PCNA In Human Ovarian Epithelial Cancer

Objective: To explore the alteration and the possible mechanism of tumor suppressor gene P16 in the progression of ovarian carcinoma. Methods: Using immunohistochemical and in situ hybridization techniques. The expression of P16, PCNA and their relationship with clinicopathological parameters were examined in 40 cases of ovarian epithelial cancers, 12 cases of borderline ovarian neoplasms and 16 cases of benign ovarian neoplasms. Results: â‘ The positive rates of P16 protein among the malignant, borderline and benign ovarian neoplasms were 77.5%, 41.67% and 12.5%. The strong positive rates were 65%, 16.67%, 0, respectively (P<0.001). The expressive rate and intensity of P16 were associated with clinical stages and survival time of patients (P<0.05). P16 protein was positive in most patients of G3, advanced stages or short survival time. â‘¡The PCNA index in G2~G3, advanced stages or short survival time was higher than those in G1, early stages or long survival time. â‘¢There was positive correlation between the expression of P16 and PCNA. â‘£Age, lymph node metastasis and expression of PCNA were the prognosis factors of ovarian carcinoma. Conclusions: The over-expression of P16 gene may be involved in ovarian epithelial cancer. The detection of P16, PCNA can evaluate the malignant degrees and may predict prognosis of ovarian carcinoma.